FDA’s MDMA rejection delays PTSD treatment options

3 weeks ago 12

The FDA's rejection of MDMA-assisted psychotherapy for PTSD has prolonged the availability of treatments, leaving many veterans and millions suffering from PTSD without access to effective treatments, and the FDA has failed to step up to address the mental health challenges.

*** Disclaimer: This Article is auto-aggregated by a Rss Api Program and has not been created or edited by Bdtype.

(Note: This is an unedited and auto-generated story from Syndicated News Rss Api. News.bdtype.com Staff may not have modified or edited the content body.

Please visit the Source Website that deserves the credit and responsibility for creating this content.)

Watch Live | Source Article